Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PASSIFLORE: [68Ga]Ga-PENTIXAFOR PET-CT in SCLC
NCT07007325Phase 1Not yet recruiting
- Sponsor
- Institut Cancérologique de l'Ouest
- Start
- Sep 2026
- Primary completion
- Sep 2028
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pentixafor in small cell lung cancer (SCLC), sponsored by Institut Cancérologique de l'Ouest. Primary endpoint: Concordance of tumoral lesions detected between [68Ga]Ga-PentixaFor PET-CT and [18F]FDG PET-CT at diagnosis at 30 days. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
pentixafor
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07007325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07007325.